QIAGEN expands QIAGEN Clinical Insight software to support all major sequencing platforms and assay types

Adding QCI Analyze Universal to NGS bioinformatics offering, plus immuno-oncology content and additional features in analysis and interpretation

Hilden, Germany, and Germantown, Maryland, October 29, 2018 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of major enhancements to QIAGEN Clinical Insight (QCI) bioinformatics solutions to deliver expanded Sample to Insight workflows for clinical next-generation sequencing (NGS). QIAGEN introduced QCI Analyze Universal for full end-to-end workflow support of all major clinical sequencing platforms and assay types, along with expanded QCI capabilities for interpretation of biomarkers in immuno-oncology as well as other enhancements, at the Association for Molecular Pathology (AMP) Annual Meeting & Expo from November 1-3, 2018, in San Antonio, Texas.

“QIAGEN Clinical Insight already is the leading integrated solution for NGS analysis and interpretation, and expanding QCI to integrate with all clinical sequencing tools makes it even more valuable for labs in analyzing and interpreting next-generation sequencing data in a broad range of applications,” said Dr. Jonathan Sheldon, Senior Vice President of QIAGEN’s Bioinformatics Business Area. “At AMP 2018 we are introducing four major improvements to QCI. We continually innovate all QIAGEN bioinformatics solutions to meet customers’ needs and stay on the cutting edge of genomics and precision medicine.”

Among the changes that QIAGEN is launching in bioinformatics:

  • QCI Analyze Universal, the newest addition to the QIAGEN Clinical Insight product line, delivers proven NGS variant calling and quality control workflows designed for clinical testing labs. Coupled with QCI Interpret, the software provides full end-to-end support for all major clinical sequencing platforms and assays with industry-leading professional services to provide support additional NGS panels.
  • QIAGEN also improved QCI Interpret’s somatic cancer clinical decision support application, which now enables interpretation and reporting of tumor mutation burden (TMB) and microsatellite instability (MSI), emerging biomarkers to guide the development and use of immuno-oncology drugs. The enhanced interpretation includes reporting on TMB and MSI scores that are calculated using QIAGEN’s CLC Genomics Workbench, and visualized and reported on through QIAGEN Clinical Insight Interpret. The improved bioinformatics offering expands QIAGEN’s footprint in immuno-oncology, which is further strengthened with the launch of QIAGEN’s novel QIAseq TMB panel for research applications at AMP.
  • QCI Interpret assay support was expanded to include pipelines pre-configured with a best practices filter for clinical exome/genome cases, including Sanger validation and variant-to-phenotype reporting. The software leverages proven technology from QIAGEN’s Ingenuity Variant Analysis product.
  • A new variant directory search feature in QCI Interpret enables clinicians the ability to store, manage and view prior laboratory observations and variant classifications in lab-specific variant databases. Laboratories can query their test result histories across prior reported cases, and to identify previously assessed variants for re-assessment purposes per CLIA-CAP requirements.

QIAGEN Clinical Insight is an integrated clinical decision-support solution for assessing next-generation sequencing data. Powered by the QIAGEN Knowledge Base, QCI can annotate, interpret and report NGS variants in the context of over 10 million relevant biomedical findings while building the user’s internal experiential knowledge base. The best-in-class workflow minimizes the complexity, time and cost of determining clinical significance and actionability of NGS variants. For more information, please visit https://www.qiagenbioinformatics.com/clinical-bioinformatics-portfolio/.

QIAGEN’s presence at AMP 2018 (October 31 – November 3)

At this year’s annual AMP meeting, around 50 scientific abstracts will feature solutions ranging across QIAGEN’s Sample to Insight workflow. QIAGEN will demonstrate novel Sample to Insight solutions, including the NeuMoDx 96 and QIAstat diagnostic systems recently launched in Europe, and meet with AMP attendees in Booth #607. In addition, QIAGEN will present three corporate-sponsored workshops on October 31:

  • 2:00-2:50 p.m. – “A complete end-to-end NGS solution for clinical cancer research
  • 3:00-3:50 p.m. – “Improving syndromic respiratory testing with QIAGEN’s DiagCORE system
  • 4:00-4:50 p.m. – “Identification of inherited genetic risk factors of pancreatic cancer using a targeted sequencing approach in a large cohort

For details on QIAGEN’s presence at AMP 2018 please visit http://amp.qiagen.com.


QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective workflows. QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare), Applied Testing (primarily forensics), Pharma (pharma and biotech companies) and Academia (life sciences research). As of September 30, 2018, QIAGEN employed approximately 4,900 people in over 35 locations worldwide. Further information can be found at http://www.qiagen.com.

Forward-Looking Statement

Certain statements contained in this press release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein relating to QIAGEN’s products, launches, regulatory submissions, collaborations, markets, strategy, taxes or operating results, including without limitation its expected sales, adjusted net sales and adjusted diluted earnings per share results, are forward-looking, such statements are based on current expectations and assumptions that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations, regulatory processes and dependence on logistics); variability of operating results and allocations between customer classes; the commercial development of markets for our products to customers in academia, pharma, applied testing and molecular diagnostics; changing relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN’s products (including fluctuations due to general economic conditions, the level and timing of customers’ funding, budgets and other factors); our ability to obtain regulatory approval of our products; difficulties in successfully adapting QIAGEN’s products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitors’ products; market acceptance of QIAGEN’s new products and the integration of acquired technologies and businesses; and the other factors discussed under the heading “Risk Factors” contained in Item 3 of our most recent Annual Report on Form 20-F. For further information, please refer to the discussions in reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission (SEC).

Social Sharing